Audio samples
coming soon.
We have a core management team of executives and scientists, with a total of seventy years of pharmaceutical, biotechnology, scientific and financial management experience.
Malcolm Skolnick, PhD, JD – Chairman/President and CEOMalcolm Skolnick received his Ph.D. in Physics from Cornell University and JD from the University of Houston Law Center.Prior to joining the CytoGenix, Dr. Skolnick held academic positions in the Graduate School of Biomedical Sciences and the School of Public Health of the University of Texas Health Science Center at Houston.He is currently an Adjunct Professor in the School of Public Health where he formerly served as Professor of Technology and Health Law.Prior to joining the School of Public Health, Dr. Skolnick managed the Health Science Center's Office of Technology Management and oversaw the University's activities in protecting and licensing its paten portfolio of technology.While at UTHSC-H, Dr. Skolnick several clinical trials in pain management, smoking cessation and reduction of withdrawal symptoms in drug addiction.
Dr. Skolnick is a registered patent attorney, patented inventor and licensed to practice in Texas.Dr. Skolnick has been active in patent prosecution and licensing for selected clients and has served as an expert witness in intellectual property, product liability, and accident reconstruction matters.
Frank Vazquez – Executive Vice President and COOPrior to joining CytoGenix, Mr. Vazquez was a consultant specializing in life science start-up enterprises.He was the founding President/CEO of Lark Technologies, Inc. and Medical Metrics, Inc.For the past 13 years, Mr. Vazquez has been engaged by BCMT, Inc. the commercialization subsidiary of Baylor College of Medicine, the University of Texas Health Science Center-Houston and individual clients to organize and start several new medical and biotechnology companies.Mr. Vazquez previously held management positions with CooperVision, Inc., Booz Allen and Hamilton, ITT Corporation and IBM.He holds a B.S. from Columbia University.
Lawrence Wunderlich – Chief Financial OfficerMr. Wunderlich worked as a financial consultant at the investment-banking firm of Josephthal and Company. Prior to his employment with Josephthal, Mr. Wunderlich co-owned The Language Loop a translation and interpreting service provider to international companies. Mr. Wunderlich is fluent in German and Russian.
Mr. Wunderlich attended the University of Vienna and Manhattan College in Riverdale, New York.
Yin Chen, PhD – Vice-president of Research & DevelopmentDr. Chen earned this Ph.D. in Molecular Biology & Biochemistry at the University of Maine in 1996. Subsequently, he was a post-doctoral fellow at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. In 1999, he joined InGene, Inc. of St. Louis as senior research scientist and then CytoGenix, as chief research scientist in February 2000. He is one of co-inventors of our company's proprietary ssDNA expression systems.
Mr. Fogle worked with Josephthal & Co. Investment Bankers for four years with CFO Lawrence Wunderlich. Also, for three years, Mr. Fogle worked for Western Geophysical as a geophysicist and Team Leader.
Mr. Fogle graduated from the University of Texas at Austin with a degree in Economics/History and with concentrations in Biology and Natural Sciences.
Harilyn McMicken, BS, MT(ASCP) – Senior Laboratory DirectorHarilyn W. McMicken graduated from Abilene Christian University and University of Texas at Galveston. She has done postgraduate work at the University of Texas School for Biomedical Sciences in Houston, Texas.Prior to her employment, Ms McMicken was Senior Research Assistant for 23 years in the Department of Pediatrics at Baylor College of Medicine.Her responsibilities and expertise lie in the areas of molecular biology and laboratory and personnel management.
Our Scientific Advisory Board is comprised of leading scientists and clinician authorities in the fields of dermatology, cancer research and gene therapy.
Yin Chen, PhD, Chairman of SABDr. Chen earned this Ph.D. in Molecular Biology & Biochemistry at the University of Maine in 1996. Subsequently, he was a post-doctoral fellow at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. In 1999, he joined InGene, Inc. of St. Louis as senior research scientist and then CytoGenix, as chief research scientist in February 2000. He is one of co-inventors of our company's proprietary ssDNA expression systems.
Cy A. Stein, MD PhDBrown University (BA), Stanford University (PhD in Organic Chemistry), Albert Einstein College of Medicine (MD), and New York Hospital-Cornell Medical Center (Internship and Residency in Internal Medicine).Dr Stein was a Clinical Associate and Senior Staff Fellow at The National Cancer Institute, Bethesda, Maryland.He is currently an Associate Professor of Pharmacology and Clinical Medicine at Columbia University, College of Physicians and Surgeons, in New York.
In addition to his clinical and faculty activities, he is Co-Editor-in-Chief of Antisense and Nucleic Acid Drug Development, sits on 7 Editorial Advisory Boards, including Nucleic Acids Research, serves on 8 Scientific Advisory Boards including Genta (Berkeley Heights, NJ), Targent (New York, NY), A3D (Heidelberg, Germany), and is an Ad hoc Reviewer for over twenty peer review journals.Dr Stein is the author of 97 peer review journal articles.He has written 56 book chapters, reviews and editorials, and he has six patents issued and four patents pending.
Peter Glazer, MD, PhDDr. Glazer holds academic degrees from Harvard (BA), Oxford (MS), and Yale (Ph.D.) and a Medical Degree from Yale University School of Medicine where he is an Associate Professor of Therapeutic Radiology and Genetics.His research interests include gene targeting and gene therapy, genetic instability in cancer, mutagenesis, and DNA repair.
Alan Gewirtz, MD, PhDDr. Gewirtz is currently a Member-Institute for Human Gene Therapy, a Professor of Internal Medicine, and a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. He is also a Member of the Graduate Group in Cell and Molecular Biology and the Leader of the Stem Cell Biology and Therapeutics Program at the University of Pennsylvania Cancer Center.
A respected leader in antisense research, Dr. Gewirtz earned a BA at Colgate University in Marine Biology, received his MA from the State University of New York at Buffalo and an MD from the University at Buffalo, School of Medicine and Biomedical Sciences. He was a Resident in Medicine at Mt. Sinai Hospital, N.Y., a Fellow in Hematology/Oncology at Yale University and a Research Associate in Medicine at Yale University School of Medicine.
Madeleine Duvic, MDDr. Duvic is a Professor of Medicine Chief, Section of Dermatology, and Associate Medical Director of the Melanoma Skin Center at the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Duvic received her B.A. from Rice University, magna cum laude, as a National Merit Scholar and her M.D. from Duke University Medical School.
Charles A. Conrad, MDDr. Conrad is Board Certified in Psychiatry & Neurology and is currently Director of the Neuro Center at M.D. Anderson Hospital and Tumor Institute in Houston, Texas. He is also an Associate Professor in the Department of Neuro-Oncology. In addition to his clinical practice in neuro-oncology, he conducts research in molecular biology related to genetic factors in tumor genesis and in anti-sense technology.
Mark R. Emmett, PhDDr. Emmett is Associate Director and Director of Biological Applications of the Ion Cyclotron Resonance Center for Interdisciplinary Magnetic Resonance, National Magnetic Field Laboratory of Florida State University. Dr. Emmett's research centers on molecular biological applications in neurochemistry and neuropharmacology.
Stephen M. Hewitt, MD, PhDDr. Hewitt is currently conducting medical research as a resident in Anatomic Pathology in the Laboratory of Pathology, National Cancer Institute, and National Institute of Health.
Malcolm Skolnick, PhD, JD – Chairman/President and CEO
Frank Vazquez –Executive Vice President/COO
Lawrence Wunderlich – Chief Financial Officer, Treasurer, Secretary
Scott E. Parazynski M.DDr. Parazynski is a graduate of Stanford University and Stanford Medical School and pursued clinical training at the Brigham and Women's Hospital (Boston, MA) and emergency medicine residency training in Denver, CO. He has published articles in the field of space physiology and has expertise in human adaptation to stressful environments. Dr. Parazynski is a member of the Aerospace Medical Association, the American Society for Gravitational and Space Biology. He has received numerous special honors, including the National Institutes of Health Pre-doctoral Training Award in Cancer Biology, NASA Graduate Student Researcher's Award and Research Honors Award from Stanford Medical School.
Dr. Parazynski has been an astronaut since 1992 and has logged over 262 hours in space. He first flew in 1994 on the Atmospheric Laboratory for Applications and Science (ATLAS-3) mission, which was part of an on-going program to determine the Earth's energy balance and atmospheric change over an 11-year solar cycle. During this mission, he and his crewmates also evaluated the Interlimb Resistance Device, a free-floating exercise he developed to prevent musculoskeletal atrophy in microgravity.
Michael Walters, L.P.T.Mr. Walters has been a director since February 1995 and is a licensed physical therapist and has been in private practice for over 36 years. During this time he has been associated with the Brook Army Hospital Burn Center in San Antonio, Texas.
